Latest News for: pik3ca
Edit
Phase 3 VIKTORIA-1 HR+/HER2-/PIK3CA MT Trial Results – June 2, 2026 (bcbf3a) (Celcuity Inc)
Public Technologies 03 Jun 2026
). The text version of this document is not available ... Disclaimer. Celcuity Inc.
Edit
A randomized, open-label, phase 3 study of gedatolisib fulvestrant ± palbociclib vs standard of care in HR /HER2−/PIK3CA-mutant (MT) advanced breast cancer (VIKTORIA-1 Study 2) (Celcuity Inc)
Public Technologies 02 Jun 2026
). The text version of this document is not available ... Attachments Permalink. Disclaimer.
Edit
Celcuity’s Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with HR+/HER2- Advanced Breast Cancer (Form 8-K) (Celcuity Inc)
Public Technologies 02 Jun 2026
Celcuity's Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial.
Edit
U.S. Food and Drug Administration Approves FoundationOne®CDx as a Companion Diagnostic for Itovebi™ (inavolisib) to Identify Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation (Foundation Medicine Inc)
Public Technologies 02 Jun 2026
Edit
Celcuity to Hold Conference Call to Discuss Results for the PIK3CA Mutant Cohort of the ...
Nasdaq Globe Newswire 01 Jun 2026
Edit
Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies (Form 8-K) (Relay Therapeutics Inc)
Public Technologies 19 May 2026
Edit
Celcuity’s Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort (Form 8-K) (Celcuity Inc)
Public Technologies 01 May 2026
HR+/HER2- breast cancer is the most common subtype of breast cancer, accounting for approximately 70% of all breast cancers.2 Among this breast cancer subtype, approximately 40% have PIK3CA mutations.
Edit
Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort (Celcuity Inc)
Public Technologies 01 May 2026
HR+/HER2- breast cancer is the most common subtype of breast cancer, accounting for approximately 70% of all breast cancers.2 Among this breast cancer subtype, approximately 40% have PIK3CA mutations.
Edit
Caledonian Record
10 Mar 2026
Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1
As previously presented, gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and gedatolisib + fulvestrant (“gedatolisib doublet”) reduced the risk of disease progression or death versus fulvestrant by 76% and 67%, respectively ....
Edit
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer (Celcuity Inc)
Public Technologies 10 Mar 2026- 1